Shares of Mylan N.V. MYL have gained 7.6% in the last three months, as against the industry’s decline of 3.7%. View photos Mylan’s fourth-quarter results were mixed with the bottom line exceeding expectations but the top line lagging the same due to ...
Yahoo! · 2mon
"We are very satisfied with the agreement reached with Mylan for the acquisition of the rights to Cystagon ... is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271 ...
GlobeNewswire · 1mon
During the public outcry that followed, CEO Heather Bresch was called to testify before Congress in fall 2016 and Mylan's stock price was hammered. Still, the price of an EpiPen didn't change, and Chairman and former CEO Robert Coury walked away with $97 ...
The generic drug company's move is a blow to the Tel Aviv Stock Exchange's recovery prospects. Generic drugs company Mylan has announced its intention of delisting from the Tel Aviv Stock Exchange. Mylan has been traded in Tel Aviv since November 2015 ...
globes.co.il · 6mon
It noted that the company's market capitalization has swelled to more than $20 million from about $3 million over the last 15 years, and its stock price also has soared over the longer time frame. "During Mr. Coury's long tenure, Mylan has delivered strong ...
Mylan (MYL) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Mylan (MYL) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Mylan's shares dropped after it said that delays in launching key new drugs and lower prices for generics in the United States will hurt its profitability this and next year. Fred Katayama reports. Mylan's stock plunged after the maker of Epi-Pen gave a ...
ロイター · 9mon